Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. healthcare vote seen as litmus test of Trump’s clout

Published 03/23/2017, 09:05 AM
Updated 03/23/2017, 09:05 AM

Investing.com – The expected vote in the House of Representatives later Thursday is seen by analysts as a litmus test of President Donald Trump’s future ability to deliver on his pro-business agenda.
Wall Street suffered heavy losses Tuesday as doubts emerged about Trump’s pledges for huge tax cuts, $1 trillion spending on infrastructure and cutting red-tape weighing on business.
The run-up in stocks since the November election has been premised on the so-called pro-growth Trump agenda.
Corporate tax cuts would likely boost earnings per share as would deregulation by cutting costs, while sparking more investment.
Overhauling infrastructure would support industrial companies and push up economic growth.
Concerns also remain that the Trump administration could be distracted by a FBI probe into possible Russian interference in the presidential election campaign and connections to the Trump camp.
If the bill is passed it could depress safe-haven assets such as gold and U.S. Treasuries and weigh on the healthcare sector.
A positive vote would benefit major indices and their related ETFs.

Latest comments

Nice update thank you very much for sharing, i will take this into consideration.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.